10-K: INNOVATE Corp. Faces Going Concern Amid Debt Refinancing, Asset Sales

INNOVATE Corp. reported a significant net loss in 2025 and faces substantial doubt about its ability to continue as a going concern, prompting strategic asset sales and debt refinancing efforts.

Summary

• INNOVATE Corp. is a diversified holding company with three operating segments: Infrastructure (DBM Global Inc. DBMG), Life Sciences (Pansend Life Sciences, LLC), and Spectrum (HC2 Broadcasting Holdings Inc.).
• The company reported a net loss attributable to INNOVATE Corp. of $60.6 million for the year ended December 31, 2025, an increase from $34.6 million in 2024.
• Total revenue increased by $138.9 million to $1,246.0 million in 2025, primarily driven by the Infrastructure segment.
• Income from operations decreased by $11.3 million to $28.7 million in 2025, mainly due to a net decrease in gross profit and other operating income, partially offset by reduced SG&A expenses.
• Interest expense increased by $14.5 million to $89.0 million in 2025, largely due to debt refinancing transactions and increased principal balances.
• The company has commenced a sales process for its Infrastructure (DBMG) and Spectrum segments due to missed milestone covenants in its 2027 Senior Secured Notes indenture.
• As of December 31, 2025, total outstanding principal debt was $687.2 million, with $581.4 million classified as current due to contingent mandatory prepayment provisions related to asset sales.
• The company's cash and cash equivalents, excluding restricted cash, increased to $112.1 million as of December 31, 2025, from $48.8 million in 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the explicit 'going concern' warning, significant net losses, and the mandatory sale of core operating segments (Infrastructure and Spectrum) driven by missed debt covenants, despite some revenue growth and strategic debt refinancing.

Positives

• Total revenue increased by $138.9 million to $1,246.0 million in 2025, primarily driven by the Infrastructure segment's commercial structural steel fabrication and erection business.
• Life Sciences segment revenue increased by $2.7 million to $12.5 million, mainly from increased Glacial Spa and Glacial fx unit sales outside North America and higher consumable sales in North America.
• MediBeacon, an equity investee in the Life Sciences segment, received FDA approval for its Transdermal GFR Measurement System (TGFR) in January 2025 and for its next-generation TGFR Reusable Sensor in December 2025.
• MediBeacon also received full regulatory approval from China's National Medical Products Administration (NMPA) for its TGFR Monitor and Sensor in October 2025.
• The company successfully refinanced significant portions of its debt in August 2025, extending maturities for its 2027 Senior Secured Notes, 2027 Convertible Notes, Revolving Line of Credit, and CGIC Promissory Note.
• DBMG, the largest subsidiary, is operationally profitable and maintains a strong financial position with its lenders.

Negatives

• Net loss attributable to INNOVATE Corp. increased significantly to $60.6 million in 2025 from $34.6 million in 2024.
• The company faces substantial doubt about its ability to continue as a going concern within one year due to upcoming debt maturities and potential breaches of cross-default provisions.
• Interest expense rose by $14.5 million to $89.0 million in 2025, driven by increased principal balances and higher interest rates from debt refinancing.
• Loss from equity investees increased by $3.6 million to $5.9 million, primarily due to higher recognized losses from MediBeacon.
• The Spectrum segment's revenue decreased by $2.5 million to $23.2 million, attributed to customer terminations and a downturn in the direct response advertising market.
• The company failed to meet the September 1, 2025, milestone for a bona fide bid or term sheet related to a potential sale of its operating subsidiaries, as required by the 2027 Senior Secured Notes Indenture, necessitating a sales process for DBMG.
• R2 Technologies has a $47.9 million senior secured promissory note due to Lancer Capital by August 1, 2026, with an effective interest rate of 17.0% as of December 31, 2025, posing a significant liquidity risk if not repaid or refinanced.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to upcoming debt maturities and potential non-compliance with debt covenants.
• High levels of indebtedness and restrictive covenants in debt and preferred stock instruments limit operational flexibility and require asset dispositions.
• Dependence on distributions from subsidiaries for cash flow, which can be restricted by subsidiary financing agreements and legal limitations.
• Inability to generate sufficient cash flows from operations to meet debt service obligations and fund working capital needs.
• Loss of key management or inability to attract and retain skilled personnel could adversely impact business operations.
• Potential material weaknesses in internal controls over financial reporting could affect financial reporting accuracy and investor confidence.
• Overall tightening of the labor market and increases in labor costs may adversely affect business and results of operations.
• Fluctuations in foreign exchange rates and inflation may adversely impact results of operations and financial condition.
• Intense competition for acquisition and business opportunities, as well as within operating segments, could limit market share and earnings.
• Cyber-attacks and other privacy or data security incidents pose risks to information systems, data confidentiality, and operational continuity.
• Unpredictable timing of DBMG's construction contracts and potential cost overruns on fixed-price contracts could materially affect financial results.
• Reliance on subcontractors and third-party vendors, particularly for steel and steel components, exposes DBMG to supply chain disruptions and cost increases.
• Pansend's operating results may fluctuate significantly due to the timing and cost of R&D, regulatory approvals, and market competition in the life sciences industry.
• R2 Technologies' success depends on customer demand and patient satisfaction with elective aesthetic procedures, which are influenced by economic conditions and marketing efforts.
• Failure to obtain or maintain necessary FDA or foreign market clearances and approvals for Life Sciences products could hinder distribution and marketing.
• Misuse of Life Sciences products by customers or medical professionals could lead to product liability lawsuits and regulatory actions.
• The Spectrum segment operates in highly competitive markets, facing competition from other broadcast stations, streaming services, and digital platforms, which could reduce market share and advertising revenue.
• FCC regulations and potential legislative changes in the broadcasting industry could significantly impact Spectrum's operations and license renewals.

Future Outlook

INNOVATE Corp. expects its future strategic focus to shift to operating and managing its remaining portfolio of companies and building value organically and inorganically following the required sales of its Infrastructure and Spectrum segments. The company will continue to evaluate strategic and business alternatives, including potential acquisitions and dispositions, and may raise capital through debt or equity securities. The Life Sciences segment anticipates continued investment in product research and development, and R2 Technologies expects to launch initial sales of its TGFR System to select academic medical centers in Q1 2026 in the United States and China. The company is exploring commercial opportunities in datacasting on its Spectrum platform for incremental revenue.

Management Comments

• Management has initiated sales processes for the Infrastructure and Spectrum segments and has been actively assessing a range of potential options to optimize the company's operational and financial position.
• Paul K. Voigt, Interim CEO, is involved with sourcing deals and capital raising for the company.
• Management believes that the company's segments are well positioned to take advantage of current trends in today's economy and that there is opportunity to build value organically and inorganicallly in these segments.
• Management plans to alleviate going concern conditions through various initiatives, including pursuing asset sales, potentially refinancing debt, and raising additional capital.

Industry Context

StockSavvy.ai notes that INNOVATE Corp. operates as a diversified holding company, exposing it to varied industry dynamics. The Infrastructure segment (DBMG) benefits from its position as one of the largest players in a fragmented construction market, leveraging integrated services for complex projects. The Life Sciences segment (Pansend) is in a highly competitive and dynamic medical technology and aesthetic product market, characterized by rapid technological development. MediBeacon's FDA approvals for its kidney function assessment system position it in a growing healthcare diagnostics market. The Spectrum segment (HC2 Broadcasting) faces increasing competition from streaming services and digital platforms, necessitating adaptation to new broadcast technologies like ATSC 3.0 to explore new revenue streams like datacasting. The company's strategy of divesting non-core assets to focus on remaining segments aligns with broader trends of corporate streamlining and value creation in holding companies.

Comparison to Industry Standards

• DBMG's typical utilization per facility ranging from 84% 94% and a sales pipeline of approximately $10.6 billion in potential revenue generation indicates strong operational capacity and market presence within the structural steel and construction services industry.
• R2 Technologies' CryoAesthetics technology is described as a 'breakthrough technology unlike any other currently available in the marketplace,' suggesting a competitive advantage in the aesthetic dermatology market, which is otherwise characterized by rapid technological development and product innovations.
• MediBeacon's Transdermal GFR System (TGFR) received FDA Breakthrough Device designation, indicating its potential to provide more effective patient management compared to existing kidney function assessment tools, which often require multiple blood draws or urine analysis and sophisticated lab analysis.
• The broadcasting industry faces increasing competition from streaming services and digital platforms, which have taken market share from Over-The-Air (OTA) broadcast stations. INNOVATE's Spectrum segment, with mostly LPTV and Class A stations, has less signal coverage than Full Power stations, placing it at a competitive disadvantage in attracting programmers and viewers compared to larger broadcasters like Sinclair Broadcast Group or Nexstar Media Group, which have broader reach and MVPD carriage rights.

Management Changes

Corporate Governance

Legal Proceedings

• GrayWolf Integrated Construction Company, a DBM Global subsidiary, received a draft Collective Action Complaint alleging failure to properly pay hourly employees due to automatic rounding of punch times and exclusion of per diems from overtime calculations. GrayWolf intends to contest the allegations and has entered into a Tolling Agreement with the Plaintiff.

Related Party Transactions

• Lancer Capital, an investment fund led by Avram A. Glazer (Chairman of the Board and largest stockholder), participated in a Rights Offering and Concurrent Private Placement in 2024, purchasing Series C Preferred Stock which later converted to common stock.
• As of December 31, 2025, Lancer Capital held $2.2 million of the company's 2027 Convertible Notes, earning $0.2 million in interest in 2025.
• Continental General Insurance Company (CGIC), a former significant shareholder, holds the company's Series A-3 and Series A-4 Preferred Stock.
• As of December 31, 2025, the company owed CGIC $45.9 million in principal amount of a subordinated secured promissory note, which was amended in August 2025 to extend maturity to April 30, 2027, and included the exchange of preferred stock and accrued dividends for additional principal.
• R2 Technologies has a $47.9 million senior secured promissory note due to Lancer Capital by August 1, 2026, with an effective interest rate of 17.0% as of December 31, 2025.
• R2 Technologies recognized $3.6 million in revenue from sales and profit-sharing agreements with a subsidiary of Huadong, a related party, in 2025.
• Share-based compensation and royalty expenses related to Blossom Innovations, LLC, an investor in R2 Technologies, totaled $0.3 million in 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and conversion of convertible notes/preferred stock. The 'going concern' warning and mandatory asset sales create substantial uncertainty and potential for share price volatility and loss of investment.
• **Employees**: The sales processes for Infrastructure and Spectrum segments could lead to changes in employment, management, or operational focus for employees within those segments. Labor market tightening and increased labor costs could impact compensation and benefits.
• **Customers**: DBMG's ability to secure and complete large construction projects, and R2 Technologies' ability to deliver and support aesthetic medical devices, directly impacts customer satisfaction and project continuity. Delays in regulatory approvals or product issues could affect customer trust.
• **Suppliers**: DBMG's reliance on a few key steel suppliers makes it vulnerable to supply chain disruptions, price fluctuations, and changes in supplier relationships, potentially affecting project timelines and costs.
• **Creditors**: The company's substantial indebtedness and upcoming maturities, coupled with the 'going concern' warning and mandatory asset sales, pose significant risks to creditors regarding timely repayment and collateral value. The debt refinancing efforts aim to manage these obligations but highlight underlying financial stress.

Next Steps

• Continue the sales process for the Infrastructure (DBMG) and Spectrum (HC2 Broadcasting) segments to meet debt covenants and optimize the capital structure.
• MediBeacon expects to begin initial sales of its TGFR System to select academic medical centers in the first quarter of 2026 in the United States and China.
• Management will continue to monitor events and circumstances related to the sales processes and perform interim impairment testing if facts and circumstances change.
• The company will continue to evaluate the impact of the OBBBA (One Big Beautiful Bill Act) as additional guidance becomes available.
• The March 1, 2026, milestone for a fully executed purchase agreement for DBMG has been extended to April 1, 2026.
• The March 1, 2026, milestone for an executed letter of intent regarding an HC2B sale was extended to March 27, 2026.
• R2 Technologies received an additional $0.3 million in intercompany convertible 13.0% notes from Pansend in February and March 2026.

Key Dates

Recommendation

The explicit 'substantial doubt about the Company's ability to continue as a going concern' is a critical red flag for investors. This, combined with significant net losses, rising interest expenses, and the mandatory sale of core operating segments (Infrastructure and Spectrum) due to missed debt covenants, indicates severe financial distress. While debt refinancing has occurred, the reclassification of a large portion of debt as current ($581.4 million) underscores immediate liquidity challenges. The company's future is highly uncertain, dependent on successful asset sales and further capital raises, which are not guaranteed on favorable terms. The risks of further dilution, default, and potential bankruptcy are substantial, making the stock a strong sell for seasoned investors.

Keywords

Diversified Holding Company, SEC Filing, 10-K, Debt Refinancing, Asset Sales, Going Concern, Infrastructure, Life Sciences, Spectrum, DBM Global, Pansend, R2 Technologies, MediBeacon, HC2 Broadcasting, Net Loss, Revenue Growth, Interest Expense, Covenants, FDA Approval, Financial Performance, Risk Management, Corporate Governance